Transparency Market Research (TMR) has published a new report on the HIV/AIDS diagnostics market for the forecast period of 2019–2027. According to the report, the global HIV/AIDS diagnostics market was valued at ~US$ 3 Bn in 2018, and is projected to expand at a CAGR of ~9% from 2019 to 2027.
- HIV/AIDS Diagnostics: Overview
HIV infection can be identified either by the detection of HIV-specific antibodies in the blood or by demonstrating the presence of the virus by nucleic acid detection using polymerase chain reaction, p24 antigen testing, or by growing the virus in cell culture. Antibody testing is a method most commonly used to diagnose the HIV infection.Apart from diagnostic HIV testing, laboratories also offer quantitative PCR (RNA) testing (viral load), which helps in determining the initiation of drug therapy and monitoring of the effectiveness of the therapy. HIV genotyping is a newer addition to patient management, and is used to track the development of drug resistance and guide the modification of antiretroviral drug selection.
In the virology test of HIV, both, HIV RNA and proviral DNA are amenable to assay. The major application of RNA assay in HIV medicine is in the measurement of viral load, which is essential to gauge the efficacy of antiretroviral therapy. Proviral DNA is incorporated in host cells, of which, the peripheral blood mononuclear cells (PBMC) are the most accessible for testing. Both, proviral DNA and HIV RNA may be tested for diagnosis.A quicker test checks for HIV antigen, a protein produced by the virus immediately after infection. It can confirm a diagnosis soon after the infection, and allow the person to take swifter steps to prevent the spread of the virus to others.
Request a Sample of HIV/AIDS Diagnostics Market Report
- High Rate HIV, Rise in Adoption of HIV Self-tests, and Increase in Awareness about HIV Diagnosis to Drive Market
According to the WHO, HIV is a major global public health issue, having claimed more than 32 million lives. In 2018, 770,000 people succumbed to HIV-related causes, globally. There were nearly 37.9 million people living with HIV at the end of 2018, with 1.7 million newly-infected individuals. A majority of the affected population lives in lower- and middle-income countries. Of the diagnosed population, around 23.3 million people are undergoing antiretroviral therapy. Hence, rise in the prevalence of HIV is projected to increase the demand for HIV/AIDS diagnostics, which, in turn, is anticipated to boost the growth of the market.
In 2016, the WHO published the first global guidelines on HIV self-testing, in which, HIV self-testing was recommended to be offered as an additional approach to HIV testing services. Fifty nine countries have adopted HIV self-testing policies, while others are currently developing them. The market for HIV self-tests continues to evolve rapidly. According to the WHO, global HIV self-test procurement volumes exceeded 1 million in 2017, and are estimated to increase rapidly to 16.4 million by the end of 2020.